Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several ...
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 69
- Registration Number
- NCT00865124
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Hemodynamic Effects of Spironolactone in Patients With Heart Failure
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- University of Toledo Health Science Campus
- Target Recruit Count
- 18
- Registration Number
- NCT00860340
- Locations
- 🇺🇸
Medical University of Ohio, Toledo, Ohio, United States
The Effect of Amiloride and Spironolactone in Healthy Persons
- Conditions
- Interventions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2011-07-08
- Lead Sponsor
- Regional Hospital Holstebro
- Target Recruit Count
- 30
- Registration Number
- NCT00857909
- Locations
- 🇩🇰
Medical Research, Holstebro, Denmark
Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- VA Salt Lake City Health Care System
- Registration Number
- NCT00709137
- Locations
- 🇺🇸
VAMC SLC - George Wahlen VA, SLC, Utah, United States
Spironolactone for Paroxysmal Atrial Fibrillation
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2008-06-05
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00689598
- Locations
- 🇨🇳
Taichung General Hospital, Taichung, Taiwan
SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Monash University
- Target Recruit Count
- 20
- Registration Number
- NCT00604006
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
Effect of Aldosterone on Energy Starvation in Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 16
- Registration Number
- NCT00574119
- Locations
- 🇺🇸
Vanderbilt Heart and Vascular Institute, Nashville, Tennessee, United States
Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Dawnmarie DeFazio
- Registration Number
- NCT00548912
- Locations
- 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Addition of Spironolactone in Patients With Resistant Arterial Hypertension
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Jan Vaclavík
- Target Recruit Count
- 160
- Registration Number
- NCT00524615
- Locations
- 🇨🇿
Olomouc University Hospital and Palacký University School of Medicine, Olomouc, Czech Republic
Aldosterone Blockade in Heart Failure
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Justin Ezekowitz
- Target Recruit Count
- 8
- Registration Number
- NCT00523757
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.